Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Auxilium Pharmaceuticals, Inc.    AUXL   US05334D1072

Financials ($)
Sales 2014 401 M
EBIT 2014 17,5 M
Net income 2014 -163 M
Debt 2014 479 M
Yield 2014 -
Sales 2015 505 M
EBIT 2015 125 M
Net income 2015 71,5 M
Debt 2015 364 M
Yield 2015 -
PER 2014 -
PER 2015 26,05
EV / Sales 2014 5,81x
EV / Sales 2015 4,38x
Capitalization 1 850 M
More Financials
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company.It focuses on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic... 
More about the company
Surperformance© ratings of Auxilium Pharmaceuticals,
Trading Rating : - Investor Rating :
More Ratings
02/13 EXCLUSIVE : Drugmaker Endo vying for Salix takeover
02/07 AUXILIUM PHARMACEUTICALS : Endo Acquires Auxilium Pharmaceuticals
02/04 AUXILIUM PHARMACEUTICALS : Endo Completes Acquisition Of Auxilium Pharmaceutical..
02/03 AUXILIUM PHARMACEUTICALS : Endo Buys Auxilium Pharmaceuticals
01/30 AUXILIUM PHARMACEUTICALS : Endo completes $2.6bn acquisition of Auxilium
01/29 AUXILIUM PHARMACEUTICALS : Entry into a Material Definitive Agreement, Terminati..
01/27 AUXILIUM PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders, ..
01/27 AUXILIUM PHARMACEUTICALS : Announces Results from Special Meeting of Stockholder..
More news
Sector news : Biopharmaceuticals
06:06a SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharmaceutical Gears Up in Medical E-comme..
06:06a SHANGHAI FOSUN PHARMACEUTICAL : Targets Greater Insurance Capital Size
05:50a BAYER : Progress in the construction of a new Bayer MaterialScience production l..
More sector news : Biopharmaceuticals
News from SeekingAlpha
05/11 Vivus' Stendra To Get A Re-Launch
03/04 FDA imposes limits on testosterone drugs and labeling changes to warn of pote..
01/29 WINNERS CIRCLE 2014 TOP HEDGE FUND M : Healthcare Funds, Nine Of Top Ten Spots

Technical analysis trends
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions